ContractopenCA
A NOVEL LPXC INHIBITOR WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY.
National Institutes of HealthDescription
A NOVEL LPXC INHIBITOR WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY. Recipient: REVAGENIX INC Award Amount: $17.88M
Requirements
Source: USASpending.gov
Interested in this contract?
Sign up to get match scores, track opportunities, and manage proposals with AI-powered tools.
Contract Details
Value Range
Up to $17,880,000
Deadline
September 30, 2026
Geographic Scope
CA
Status
open
External Links
View Original ListingSee how well this contract matches your organization.
Get Your Match Score